"Enhancement of solubility of a poorly soluble antiplatelet aggregation drug by cogrinding technique"
DOI:
https://doi.org/10.22159/ajpcr.2018.v11i10.27136Keywords:
Ticagrelor, Stability indicating assay, Poorly soluble drug, CogrindingAbstract
Objective: The goal of this study was to formulate ticagrelor tablets with enhanced dissolution rate using cogrinding technique. However, it belongs to the biopharmaceutical classification system Class IV molecule, poorly soluble, and permeable.
Methods: Various ratios (0.2:1–1.67:1) of povidone (PVP)/drug were used in the formulations. Ticagrelor was coground with different percentage of PVP K 25 (carrier) in a mortar with a pestle for 30 min, then mixed with the rest excipients. A high-performance liquid chromatography stability indicating assay was developed to test the stability of ticagrelor in the selected formulae.
Results: The results showed that the presence of PVP in relatively high ratios compared to the drug is desirable for enhancing the dissolution rate of ticagrelor. The best-optimized formulae found were that F8 and F9 which showed good disintegration and dissolution rate of ticagrelor more than 92% after 30 min while the dissolution rate for ticagrelor standard was only 22% after 30 min. Stability studies were performed on the selected formulae F8 and F9.
Conclusion: The optimized formulae were evaluated for thickness, weight variation, hardness, friability, dissolution, and accelerated stability study for a period of 6 months. Cogrinding using PVP K 25 proved to enhance the dissolution of ticagrelor which may be due to the formation of a soluble complex between ticagrelor and PVP. The selected formulae F8 and F9 showed good stability.
Downloads
References
Angiolillo D, Capranzano P. Pharmacology of emerging novel platelet inhibitors. Am Heart J 2008;156:S10-5.
Available from: http://www.accessdata.fda.gov/drugsatfda_docs/ label/2015/022433s017lbl.pdf.
Available from: https://pdf.hres.ca/dpd_pm/00035087.PDF.
Available from: http://www.ema.europa.eu/docs/en_GB/ document_library/EPAR-Public_assessment_report/human/001241/ WC500100492.pdf.
Al-nuss R, El-zein H. Enhancement of candesartan cilexetil dissolution rate by using different methods. Asian J Pharm Clin Res 2015;8:320-6.
Jassim EZ. Formulation and evaluation of furosemide liquisolid compact. Int J Appl Pharm 2017;6:39-48.
Bharti PV, Attal RV, Munde VA, Birajdar SA, Bais S. Strategies to enhance solubility and dissolution of a poorly water soluble drug. J Innov Pharm Biol Sci 2015;2:482-94.
Friedrich H, Nada A, Bodmeier R. Solid state and dissolution rate characterization of co-ground mixtures of nifedipine and hydrophilic carriers. Drug Dev Ind Pharm 2005;31:719-28.
Yamamoto K, Nakano M, Arita T, Takayama Y, Nakai Y. Dissolution behavior and bioavailability of phenytoin from a ground mixture with microcrystalline cellulose. J Pharm Sci 1976;65:1484-8.
Sang-Chul S, In-Joon O, Yong-Bok L, Hoo-Kyun C, Jun-Shik C. Enhanced dissolution of furosemide by coprecipitating or co-grinding with crospovidone. Int J Pharm 1998;175:17-24.
Mitrevej A, Sinchaipanid N, Junyaprasert V, Warintournuwat L. Effect of grinding of b-cyclodextrin and glibenclamide on tablet properties. Part I. In vitro. Drug Dev Ind Pharm 1996;22:1237-41.
Bűhler V. Polyvinylpyrrolidone Excipients for Pharmaceuticals: Povidone, Crospovidone and Copovidone. Germany: Springer Science & Business Media; 2005.
The British Pharmacopoeia. The Stationery Office. London: Electronic Version; 2014.
U.S. FDA. Guidance for Industry: Analytical Procedures and Methods Validation: Chemistry, Manufacturing and Controls Documentation; 2000.
Available from: https://www.ich.org/fileadmin/Public_Web_Site/ICH_ Products/Guidelines/Quality/Q2_R1/Step4/Q2_R1 Guideline.pdf.
Ponnekanti K, Sundarara R. Development and validation of new RP-UPLC method for the determination of cefdinir in bulk and dosage form. Int J Pharm Pharm Sci 2018;1:187-94.
Krull IS, Swartz ME. Validation of chromatographic method. Pharm Tech 1998;22:104-19.
Ng LL. Reviewer Guidance: Validation of Chromatographic Method. FDA Center for Drug Evaluation and Research (CDER); 1994.
Available from: https://www.accessdata.fda.gov/scripts/cder/ dissolution/dsp SearchResults.cfm.
Aronson H. Correction factor for dissolution profile calculations. J Pharm Sci 1993;82:1190.
Landge SB, Jadhav SA, Vishwambar SP, Solanki PV, Bembalkar SR, Mathad VT. Development and validation of an RP-UPLC method for the determination of iloperidone, its related compounds and degradation products in bulk and dosage form. Am J Anal Chem 2014;5:969-81.
Ramesh K, Shekar CB, Khadgapathi P. Enhancement of solubility and rate of in vitro drug release profiles of poorly soluble ticagrelor by solvent evaporation solid dispersion technique. Indo Am J Pharm Res 2015;5:3580-5.
Dabhi AN, Patel DM. Spray dried dispersions: A viable approach to improve bioavailability, ticagrelor as a model drug. World J Pharm Res 2017;16:745-58.
El-maghraby MG, Ghanem FS. Preparation and evaluation of rapidly dissolving tablets of raloxifene hydrochloride by ternary system formation. Int J Pharm Pharm Sci 2016;1:127-36.
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
